Phase II study of M518101 in patients with verruca vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223883

Enrollment

Registered

2018-04-23

Start date

2018-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

verruca vulgaris

Interventions

investigational material(s) Generic name etc : M518101 INN of investigational material : pefcalcitol Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with verruca vulgaris patients

Exclusion criteria

Exclusion criteria: 1) Patients who have a history or presence of serious drug hyper sensitivity 2) Patients who have cardiac, hepatic, renal, pulmonary, blood disease considered inappropriate for participation in clinical trials 3) Patients with immunosuppression

Design outcomes

Primary

Measure	Time frame
efficacy exploratory Clearance of wart, size of wart The investigator will measure and count warts at every visit.	—

Secondary

Measure	Time frame
safety Safety assessment Adverse events, Laboratory tests	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026